Canalys:次季美國PC出貨量升17%至逾3,680萬台
調查機構Canalys發表的研究報告指,次季美國PC市場出貨量按年升17%,期內桌上電腦、手提電腦、平板及工作站出貨量合共逾3,680萬台,其中手提電腦表現最強,出貨量按年升27%,而桌上電腦亦現復甦,出貨量升23%,平板出貨量則跌1%。
按品牌劃分,HP(HPQ.US)出貨量按年升20.2%至807萬台,市佔率21.9%排第一,蘋果(AAPL.US)出貨量跌2.8%至760.3萬台排第二,而Dell(DELL.US)及聯想(00992.HK)出貨量分別排第三及第四,出貨量分別按年增10.5%及25.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.